ArticleDiscover oncology2025
Multi-omics dissection of CPNE1 reveals its prognostic value and immune-regulatory function in liver cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is known for its high malignancy and poor prognosis. Despite some progress in treatment approaches in recent years, the prognosis of HCC remains unfavorable. CPNE1 (Copine 1), a calcium-dependent phospholipid-binding protein, has been shown to be involved in the development of various cancers. However, the precise role of CPNE1 in HCC and its underlying molecular mechanisms remain unclear. This study aims to elucidate the role of CPNE1 in HCC and investigate its relationship with the immune microenvironment.
methodsIn this study, we conducted a pan-cancer analysis of CPNE1 expression and prognosis using data from the Cancer Genome Atlas (TCGA). Using a series of bioinformatics analyses, including expression, correlation, and survival analyses, we predicted the upstream miRNAs and lncRNAs of CPNE1 and explored its regulatory network through the competitive endogenous RNA (ceRNA) mechanism. Subsequently, functional enrichment analysis was conducted to explore the related functions and signaling pathways of the target genes. Finally, using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics data from the GEO database, we analyzed the spatial distribution of CPNE1 in liver cancer tissues and its expression profiles in immune cells.
resultsDifferential expression analysis revealed that CPNE1 expression is higher in hepatocellular carcinoma tissues than in adjacent non-cancerous tissues, and HCC patients with higher CPNE1 expression tend to have a worse prognosis. The SNHG6-hsa-miR-101-3p axis was identified as a promising CPNE1 upstream ncRNA pathway in HCC. Functional enrichment analysis revealed that CPNE1 is significantly enriched in several tumor-associated pathways. Single-cell sequencing and spatial transcriptomics analyses revealed that CPNE1 expression is elevated in malignant hepatocytes and immune cells, particularly in NK cells. Further cell communication analysis suggested that CPNE1 may influence the immune microenvironment of liver cancer through the MIF and PPIA-BSG signaling pathways.
conclusionCPNE1 is linked to poor prognosis in hepatocellular carcinoma (HCC) and proposes the SNHG6/hsa-miR-101-3p/CPNE1 regulatory axis. The study investigates the role of CPNE1 in modulating the immune microenvironment of liver cancer and suggests that it may serve as a biomarker for poor prognosis in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.